Meeder Asset Management Inc. Boosts Stock Position in Calithera Biosciences Inc (NASDAQ:CALA)

Meeder Asset Management Inc. grew its stake in shares of Calithera Biosciences Inc (NASDAQ:CALA) by 769.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,455 shares of the biotechnology company’s stock after acquiring an additional 7,483 shares during the period. Meeder Asset Management Inc.’s holdings in Calithera Biosciences were worth $48,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Voya Investment Management LLC raised its position in shares of Calithera Biosciences by 12.4% in the third quarter. Voya Investment Management LLC now owns 18,324 shares of the biotechnology company’s stock worth $57,000 after buying an additional 2,023 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Calithera Biosciences in the third quarter worth $95,000. Grimes & Company Inc. raised its position in shares of Calithera Biosciences by 24.6% in the fourth quarter. Grimes & Company Inc. now owns 25,300 shares of the biotechnology company’s stock worth $144,000 after buying an additional 5,000 shares in the last quarter. Beddow Capital Management Inc. raised its position in shares of Calithera Biosciences by 144.4% in the fourth quarter. Beddow Capital Management Inc. now owns 27,500 shares of the biotechnology company’s stock worth $157,000 after buying an additional 16,250 shares in the last quarter. Finally, California State Teachers Retirement System raised its position in shares of Calithera Biosciences by 43.5% in the third quarter. California State Teachers Retirement System now owns 73,521 shares of the biotechnology company’s stock worth $227,000 after buying an additional 22,298 shares in the last quarter. Hedge funds and other institutional investors own 74.19% of the company’s stock.

Shares of CALA traded up $0.25 on Thursday, hitting $4.45. 48,829 shares of the stock traded hands, compared to its average volume of 695,005. The company has a market capitalization of $279.18 million, a PE ratio of -2.27 and a beta of 2.15. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.14 and a current ratio of 8.14. The business has a 50 day simple moving average of $5.92 and a 200 day simple moving average of $4.79. Calithera Biosciences Inc has a one year low of $2.45 and a one year high of $8.04.

Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings results on Wednesday, March 11th. The biotechnology company reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.02). On average, equities analysts expect that Calithera Biosciences Inc will post -1.5 earnings per share for the current year.

A number of research firms recently commented on CALA. HC Wainwright started coverage on Calithera Biosciences in a research note on Wednesday, November 27th. They issued a “buy” rating and a $7.00 target price on the stock. BidaskClub cut Calithera Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, March 11th. SVB Leerink reissued an “outperform” rating on shares of Calithera Biosciences in a research note on Wednesday, March 11th. Finally, ValuEngine raised Calithera Biosciences from a “hold” rating to a “buy” rating in a research note on Tuesday, March 17th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $6.50.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.

See Also: Return on Equity (ROE)

Want to see what other hedge funds are holding CALA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Calithera Biosciences Inc (NASDAQ:CALA).

Institutional Ownership by Quarter for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News